Ellison D W, Campbell I C
J Neurochem. 1986 Jan;46(1):218-23. doi: 10.1111/j.1471-4159.1986.tb12949.x.
The sensitivity of alpha 2-adrenoceptors on 5-hydroxytryptamine (5-HT) nerve endings obtained from rat cerebral cortex was investigated following treatment with the antidepressant drugs desipramine (10 mg/kg/day for 21-28 days) or clorgyline (1 mg/kg/day for 21-28 days). [3H]5-HT (100 nM) was used to load cortical synaptosomes (P2) after experiments with uptake inhibitors confirmed that this concentration of amine ensured exclusive uptake into 5-HT nerve terminals. The sensitivity of K+-stimulated release of [3H]5-HT to alpha 2-adrenoceptor occupancy was assessed in a superfusion system by means of the dose-dependent inhibition of [3H]5-HT release by clonidine. This is blocked by yohimbine (1 microM), which, when administered alone, enhances release, suggesting that endogenous catecholamines released from other synaptosomes act on these alpha 2-heteroreceptors. The effect of addition of citalopram (1 microM) to superfusates suggests that some reuptake of [3H]5-HT occurs during superfusion. Of the tritium released into superfusates during "background" and K+-stimulated release, 17 and 90%, respectively is [3H]5-HT. The attenuation of K+-stimulated release by clonidine is apparently diminished by the chronic clorgyline regimen but not by desipramine. However, clorgyline elevates catecholamine levels, and this might increase endogenous noradrenaline (NA) efflux, which by competition with clonidine could appear to alter alpha 2-adrenoceptor sensitivity. This possibility was investigated by depleting NA with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). These studies showed that the apparent effect of chronic clorgyline on alpha 2-adrenoceptor sensitivity to clonidine was due to competition with increased levels of endogenous NA.(ABSTRACT TRUNCATED AT 250 WORDS)
在用抗抑郁药地昔帕明(10毫克/千克/天,持续21 - 28天)或氯吉兰(1毫克/千克/天,持续21 - 28天)治疗后,研究了从大鼠大脑皮层获取的5 - 羟色胺(5 - HT)神经末梢上α2 - 肾上腺素能受体的敏感性。在用摄取抑制剂进行的实验证实该胺浓度可确保其专一性摄取到5 - HT神经末梢后,使用[3H]5 - HT(100纳摩尔)加载皮层突触体(P2)。在灌注系统中,通过可乐定对[3H]5 - HT释放的剂量依赖性抑制作用,评估K + 刺激的[3H]5 - HT释放对α2 - 肾上腺素能受体占据的敏感性。这被育亨宾(1微摩尔)阻断,单独给予育亨宾时会增强释放,表明从其他突触体释放的内源性儿茶酚胺作用于这些α2 - 异源受体。向灌注液中添加西酞普兰(1微摩尔)的作用表明,在灌注过程中会发生一些[3H]5 - HT的再摄取。在“背景”和K + 刺激释放期间释放到灌注液中的氚中,分别有17%和90%是[3H]5 - HT。可乐定对K + 刺激释放的抑制作用在慢性氯吉兰治疗方案下明显减弱,但在地昔帕明治疗下未减弱。然而,氯吉兰会提高儿茶酚胺水平,这可能会增加内源性去甲肾上腺素(NA)外流,通过与可乐定竞争,可能会改变α2 - 肾上腺素能受体敏感性。通过用神经毒素N - (2 - 氯乙基) - N - 乙基 - 2 - 溴苄胺(DSP4)耗尽NA来研究这种可能性。这些研究表明,慢性氯吉兰对α2 - 肾上腺素能受体对可乐定敏感性的明显影响是由于与内源性NA水平升高的竞争所致。(摘要截短于250字)